The decade-long research that University of Nevada, Reno College of Science Chemistry Professor Thomas Bell has invested in the development of an extremely effective HIV/AIDS-fighting compound received an important boost recently when one of Bell’s articles made the list of the 100 most influential publications in the HIV/AIDS research field for 2006.
On International Women’s Day, the UK National AIDS Trust calls for further support for the development of microbicides and vaccines, new prevention technologies that could prevent millions of women from becoming infected with HIV.
Statement of Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, on National Women and Girls HIV/AIDS Awareness Day, March 10, 2007 :
New evidence suggests that the risk of HIV transmission may be highest in the early stages of infection. According to a study published in the April 1 issue of the Journal of Infectious Diseases, now available online, early infection accounted for nearly half of all transmission occurrences in an HIV-infected population in the province of Quebec, Canada.
At this week’s major HIV/AIDS research meeting, Pfizer presented pivotal data of its experimental medicine, maraviroc, which tackles HIV in an entirely new way. A 24 week analysis showed that approximately twice as many patients receiving maraviroc with an optimized background regimen achieved undetectable virus in the blood than if an optimized regimen was given alone.
Two anti-retroviral treatment centres (ARTCs) for free treatment to AIDS patients have been set up in Jammu and Kashmir with 1,030 HIV positive cases reported in the state till date, PTI.
Results from two ongoing Phase III studies of ISENTRESS? (raltegravir), an investigational oral integrase inhibitor, demonstrated significantly greater antiretroviral activity of ISENTRESS when used in combination with optimized background therapy (OBT) versus placebo plus OBT in treatment-experienced HIV-infected patients who had failed antiretroviral therapies (ARTs), and who had HIV virus resistant to at least one drug in each of the three available classes of oral ARTs.
A total of 373 new cases of Human Immunodeficiency Virus (HIV) were reported to the Hong Kong Department of Health (DH) last year (2006), the highest annual number ever recorded.
At this week’s major HIV/AIDS research meeting, Pfizer presented pivotal data of its experimental medicine, maraviroc, which tackles HIV in an entirely new way.
Even as the AIDS epidemic in Los Angeles County has shifted largely to Hispanics, primary-care practitioners serving this segment of the population often fail to offer either HIV testing or safer sex advice to their patients, according to a new UCLA AIDS Institute study